Inflammatix
Inflammatix is a venture-backed molecular diagnostics company developing the FDA-cleared TriVerity Test System, a rapid host-response blood test that uses machine learning to distinguish bacterial from viral infections and predict sepsis severity for hospital emergency departments.
- Company typePrivate
- Founded2016
- HeadquartersBurlingame, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Inflammatix does
Inflammatix is a venture-backed molecular diagnostics company founded in 2016 that develops host-response tests reading the immune system to diagnose acute infections and predict sepsis severity. Its flagship product, the FDA-cleared TriVerity Test System, measures 29 host immune response mRNAs from a single blood sample and, using proprietary machine learning classifiers, returns three actionable scores (bacterial infection likelihood, viral infection likelihood, and risk of severe illness within 7 days) in approximately 30 minutes on the company's compact Myrna point-of-care instrument. The company targets hospital emergency departments, intensive care units, and adjacent public health and biodefense use cases, with a sales motion built on direct enterprise deployment to hospital systems. Co-founders Tim Sweeney (MD/PhD, CEO) and Purvesh Khatri (PhD, Chief Scientist) lead the company, supported by an executive bench staffed with veterans from Outset Medical, Intuitive Surgical, Becton Dickinson, and Abbott.
Inflammatix makes money primarily through sales of its proprietary TriVerity cartridges (consumables) and Myrna instruments to hospital laboratories and emergency departments, generating recurring revenue per test performed. Secondary revenue streams include licensing royalties on intellectual property exclusively licensed from Stanford University, and partnership and collaboration revenue from pharmaceutical and device companies using TriVerity for patient stratification in clinical trials. The company has secured significant non-dilutive capital from U.S. federal agencies including BARDA, NIH, and DARPA for diagnostic development. Total disclosed venture funding exceeds $194M across multiple rounds led by Khosla Ventures, D1 Capital Partners, and Northpond Ventures, with strategic investment from OSF Healthcare System. The firm holds ISO 13485:2016 certification, FDA Breakthrough Device Designation, and FDA 510(k) clearance, and operates from Sunnyvale, California with a wholly-owned subsidiary in Lisbon, Portugal.
Inflammatix firmographics
Firmographics- Name
- Inflammatix
- Legal name
- Inflammatix, Inc.
- Website
- https://inflammatix.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Inflammatix is a venture-backed molecular diagnostics company developing the FDA-cleared TriVerity Test System, a rapid host-response blood test that uses machine learning to distinguish bacterial from viral infections and predict sepsis severity for hospital emergency departments.
- Ownership category
- akta.pro rank
Inflammatix industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
- akta.pro secondary industry
- Diagnostic & Triage Decision Support (HLACAGAA)
Keywords
Where Inflammatix is headquartered
LocationHeadquarters
- HQ city
- Burlingame
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Inflammatix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Diagnostic Test Sales: Sales of TriVerity test cartridges and Myrna instruments to hospital systems and laboratories. The test system generates recurring revenue through consumable cartridge sales for each test performed.
- Licensing Revenue: Technology licensed from Stanford University with exclusive rights to core intellectual property for host response diagnostics.
- Partnership and Collaboration Revenue: Collaborations with pharmaceutical and device companies to identify patients likely to respond to novel therapies, potentially generating milestone and royalty payments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Inflammatix product offering
Product offeringCore offering
Inflammatix develops and sells the TriVerity Test System, an FDA-cleared rapid blood test that measures 29 host immune response mRNA biomarkers and applies proprietary machine learning classifiers to deliver three actionable scores—likelihood of bacterial infection, viral infection, and severe illness within 7 days—in approximately 30 minutes from a single blood sample. The system consists of the Myrna point-of-care instrument and single-use TriVerity cartridges deployed in hospital emergency departments for triage of patients with suspected acute infection or sepsis.
Product overview
Inflammatix offers a unified product portfolio centered on host-response molecular diagnostics. The flagship offering is the TriVerity Test System, which combines a disposable TriVerity Cartridge with the Myrna Instrument platform to deliver rapid infection diagnosis and severity prediction from a single blood test in approximately 30 minutes. The system uses a proprietary 29-mRNA host response panel interpreted by machine learning algorithms to distinguish bacterial from viral infections and predict ICU deterioration risk. In parallel, Inflammatix is developing an Endotypes Program for sepsis subtype classification to guide targeted therapies, though these pipeline products remain investigational and not yet commercially marketed.
Differentiator
Problem solved
Functional benefit
Brands
- TriVerity: First-in-class molecular blood test for diagnosing infection type (bacterial/viral) and predicting illness severity in patients with suspected acute infection or sepsis. Measures 29 host immune response mRNA markers and delivers results in approximately 30 minutes.
- Myrna
Products and services
- TriVerity Test System FDA-cleared first-in-class molecular diagnostic test that measures 29 host immune response mRNAs to provide three actionable scores: likelihood of bacterial infection, likelihood of viral infection, and risk of severe illness within 7 days. Delivers results in approximately 30 minutes from a single blood sample for emergency department patients with suspected acute infection or sepsis.
- Myrna Instrument Sample-to-answer isothermal point-of-care instrument platform that runs the TriVerity cartridge. Compact benchtop device (11.5-inch footprint) requiring no regular maintenance, with room-temperature cartridge storage, LIS connectivity options, and remote result notification capabilities.
- TriVerity Cartridge Proprietary disposable cartridge containing the 29-mRNA host response assay. Single-use consumable for the TriVerity Test System, designed for room-temperature storage stability up to 9 months, generating recurring revenue per test performed.
Quantifiable outcome
- Validated in 1,222 patients across 22 sites with high sensitivity and specificity regardless of immune status or race
- +4 more outcomes
Companies that use Inflammatix
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Inflammatix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature4 records
Inflammatix partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- University of Nebraska Medical CentercoreCollaboration to deploy TriVerity host-response diagnostic test in response to hantavirus outbreak. TriVerity is being used to better understand early signatures of infection in individuals with high-risk exposures to hantavirus, providing rapid assessment of infection type and risk of deterioration.
- Biomedical Advanced Research and Development Authority (BARDA)coreFederal government partner providing funding support under contracts 75A50119C00034, 75A50119C00044, and 75A50122C00069 for development of TriVerity test system.
- National Institutes of Health (NIH)minorFederal research funding agency collaborating with Inflammatix on diagnostic development.
- DRIVe (Division of Research, Innovation, and Ventures)minorBARDA innovation initiative supporting development of diagnostics for emerging infectious diseases.
- DARPAminorDefense Advanced Research Projects Agency providing funding for early diagnostic technology development.
- SUBSPACE ConsortiumcoreSUBtyping in SePsis And Critical illnEss consortium - collaborative of leading researchers and clinicians comparing different existing subtype classifiers for sepsis. Sponsored by Inflammatix, analyzing transcriptomic data from 7,000+ patient samples across 37 cohorts worldwide.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Inflammatix competitors and assessment
Company assessmentEmerging players
- Prenosis: Develops AI-driven diagnostics for sepsis and acute care, including the Sepsis ImmunoScore. Competes with Inflammatix in applying machine learning to host-response and clinical data for early sepsis identification in hospital settings.
- DxTerity Diagnostics: Develops blood-based molecular and immune-response diagnostics, including interferon-score and immune-monitoring tests. Adjacent emerging player applying host-response biology to clinical diagnostics, comparable in technology category though currently focused on different indications.
Broad incumbents
- Cepheid (Danaher): GeneXpert system is a leading rapid molecular POCT platform used in U.S. EDs for infectious disease testing. Overlaps with Inflammatix in the rapid-molecular-diagnostic category and competes for ED instrument placements and test-menu real estate.
- QIAGEN: Provides QIAstat-Dx molecular POCT systems and sample-prep technologies relevant to rapid infectious disease diagnostics. Adjacent incumbent in the molecular POCT category where Inflammatix's Myrna instrument also competes.
- bioMérieux (BioFire Diagnostics): BioFire FilmArray panels are a dominant rapid molecular diagnostic for infectious disease in U.S. EDs. While pathogen-detection focused rather than host-response, BioFire is the most entrenched incumbent competing for ED test-menu slots and budgets.
- Roche Diagnostics: Offers a broad portfolio of hospital and ED diagnostics including Elecsys procalcitonin, cobas molecular systems, and emerging biomarker tests. A large incumbent competing for sepsis-triage test menus in the same hospital customer base.
- Abbott (Rapid Diagnostics / Alere): i-STAT and Alinity instruments are widely deployed across U.S. EDs for rapid diagnostics including lactate and infectious disease markers. Competes with Inflammatix for ED bench-space real estate and test-menu decisions; Martín Vazquez previously led Abbott Rapid Dx.
Direct peers
- Cytovale: Commercializes IntelliSep, a FDA-cleared rapid cellular biomarker test for sepsis that delivers results in under 10 minutes from a blood sample. Targets the same ED sepsis-triage workflow as TriVerity with a complementary host-immune-cell measurement approach.
- T2 Biosystems: Develops T2Bacteria and T2Candida direct-from-blood molecular diagnostics for sepsis-causing pathogens. Operates in the same ED/hospital sepsis-diagnosis segment with an alternative rapid-molecular approach to Inflammatix's host-response test.
- Immunexpress: Developer of SeptiCyte RAPID, a FDA-cleared host-response gene-expression test for sepsis diagnosis. Directly comparable to Inflammatix's TriVerity in mechanism (host mRNA signatures), clinical use case (ED/ICU sepsis triage), and customer base (hospital labs).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Inflammatix social profiles
Digital presenceInflammatix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inflammatix leadership team
Management profileNumber of profiles
Profiles12 records
Inflammatix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Inflammatix funding detail
Funding detailFunding overview
Funding rounds8 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inflammatix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inflammatix
What does Inflammatix do?
Inflammatix develops and sells the TriVerity Test System, an FDA-cleared rapid blood test that measures 29 host immune response mRNA biomarkers and applies proprietary machine learning classifiers to deliver three actionable scores—likelihood of bacterial infection, viral infection, and severe illness within 7 days—in approximately 30 minutes from a single blood sample. The system consists of the Myrna point-of-care instrument and single-use TriVerity cartridges deployed in hospital emergency departments for triage of patients with suspected acute infection or sepsis.
Is Inflammatix a public or private company?
Inflammatix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inflammatix founded?
Inflammatix was founded in 2016. It employs 51 to 100 people.
Where is Inflammatix based?
Inflammatix is headquartered in Burlingame, United States, in the North America region.
How does Inflammatix make money?
Three revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are licensing Revenue and partnership and Collaboration Revenue.
Who are Inflammatix's main competitors?
Emerging players on record are Prenosis and DxTerity Diagnostics. Broad incumbents are Cepheid (Danaher), QIAGEN, bioMérieux (BioFire Diagnostics), Roche Diagnostics and Abbott (Rapid Diagnostics / Alere). Direct peers are Cytovale, T2 Biosystems and Immunexpress.
Does Inflammatix have an API?
No public API is recorded for Inflammatix.
What industry is Inflammatix in?
Inflammatix's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLACAGAA, Diagnostic & Triage Decision Support. Its NAICS code is 325413 and its SIC code is 2835.